Search Results 1331-1340 of 19388 for hemoglobin

1. A Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Subject has a history of diabetes mellitus type 1, or uncontrolled diabetes mellitus type 2 with hemoglobin A1c (HbA1c) > 9%, or is a diabetic subject with ...

2. A Study To Evaluate APG2575 Combined With Novel Therapeutic Regimens To Treat Subjects With Relapsed Or Refractory Multiple Myeloma And Immunoglobulin Light Chain Amyloidosis - Mayo Clinic

   Hemoglobin ≥ 8 g/dL without transfusion or growth factor support within 7 days of the first dose of study drug;; Platelet count ≥ 50 x 10^9/L without ...

3. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

   Hemoglobin ≥ 7.0 g/dL;; Platelets ≥ 50 x 10^9/L;; Total bilirubin ≤ 1.5 x Upper limit of normal (ULN) (Isolated bilirubin ≥ 1.5 x ULN is acceptable if ...

4. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   Absolute neutrophil count ≥ 1,000 cells/mm3 without growth factors (within 14 days of enrollment). Hemoglobin ≥ 8 g/dL (within 14 days of enrollment) ...

5. High blood protein When to see a doctor - Mayo Clinic

   A total protein test may be done. Other, more-specific tests, including serum protein electrophoresis (SPEP), can help find the exact source, such as the liver ...

6. A Study of MTI-301 in Patients with Advanced Malignancy - Mayo Clinic

   Participation eligibility · Hemoglobin ≥ 9.0 g/dL · Absolute neutrophil count (ANC) ≥ 1500/mm3 · Platelet count ≥ 100,000/mm3 · Total bilirubin ≤ 1.5 x ULN.

7. A Study to Evaluate Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer - Mayo Clinic

   - Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable) - No prior invasive (except non-melanoma skin ...

8. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL; Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) (serum glutamic oxaloacetic ...

9. A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   Hemoglobin >8.0 g/dl. Adequate pulmonary function defined as: No or mild dyspnea (≤ Grade 1);; Oxygen saturation measured by pulse oximetry > 90% on room ...

10. PRE-I-SPY Phase I/Ib Oncology Platform Program - Mayo Clinic

    - Hemoglobin ≥ 9.0 g/dL with no blood transfusion in the past 28 days - Total bilirubin ≤ 1.5 x the upper limit of normal (ULN) - Aspartate ...